Since this trial is the first trial evaluating FAP-specific re-directed T cells in the pleural effusion, all enrolled patients will be treated with the lowest suggested number of cells [25] and monitored for the first 48h at an intermediate care unit. Here, FAP is linked to Pleural effusion.